Motexafin lutetium

Motexafin gadolinium, 24 56 Motexafin lutetium, 24 56 Moths, sex attractants of, 22 269 Motion... 

Motexafin lutetium is also in clinical trials, having completed several Phase I and II studies. The completed trials are for the photodynamic treatment of recurrent breast cancer [41,42], light-based treatment of choroidal neovascularization, [43] and the photoangioplastic reduction of atherosclerotic plaque in peripheral [19,44] and coronary arterial disease [20,45], On the basis of these studies, MLu (Antrin Phototherapy) is currently being developed for the treatment of atherosclerotic plaque. Additionally, the National Cancer Institute is testing MLu for the PDT based treatment of prostate [46,47] and cervical cancers. 

Chou, T.M. et al. (2002) Photodynamic therapy applications in atherosclerotic vascular disease with motexafin lutetium, Catheterization and cardiovascular interventions official journal of the Society for Cardiac Angiography Interventions 57, 387-394. 

Kereiakes, D.J. et al. (2003) Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment procedural and long-term results, Circulation 108, 1310-1315. 

Dimofte, A. et al. (2002) In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer, Lasers Surg. Med. 31, 305-312. 

Rockson, S.G. et al. (2000) Photoangioplasty for human peripheral atherosclerosis Results of a phase I trial of photodynamic therapy with motexafin lutetium (antrin), Circulation 102, 2322-2324. 

Griffin, G.M. et al. (2001) Preclinical evaluation of motexafin lutetium-mediated intraperitoneal photodynamic therapy in a canine model, Clin. Cancer Res. 7, 374-81. 

Hayase, M. et al. (2001) Photoangioplasty with local motexafin lutetium delivery reduces macrophages in a rabbit post-balloon injury model, Cardiovascular Research 49, 449-455. 

Antrin Motexafin lutetium Coronary PI Vulnerable plaque ... 

Yamaguchi A, Woodburn KW, Hayase M, et al. Reduction of vein graft disease using photodynamic therapy with motexafin lutetium in a rodent isograft model. Circulation 2000 ... 

I Chen Z, Woodburn KW, Shi C, et al. Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells. Arterioscler 7hromb Vase Biol 2001 21 759-764. 

A recent addition to the PDT field has been the expanded porphyrin derivatives known as texaphyrins (that is, Texas-sized porphyrins). Sessler has developed a number of these molecules. Appropriate derivatives absorb as far out as 732 nm, and provide better penetration of the light to tissues. The lutetium derivative, termed motexafin lutetium (Lutrin), is under investigation for the treatmentof breast cancer. In addition,. some derivatives appear to accumulate in atherosclerotic plaques that can line blood vessels, making the notion of photoangioplasty a real possibility. 

Several promising photosensitisers with activation wavelengths in the far-red or near infrared regions are currently in clinical trials. The structures of several clinical PDT photosensitisers are shown in Fig. 9.3. TOOKAD, a palladium bacteriochlorophyll derivative with excitation at 763 nm is currently in phase II clinical trials for the treatment of prostate cancer (via vascular targeted PDT, vide infra). Lutetium texaphyrin (motexafin lutetium, Lutex ) which combines the advantages of water solubility, selective localisation, and the ability to be activated... 

Hayase, M., Woodburn, K.W., Perhoth, J., Miller, R.A., Baumgardner, W., Yock, P.G., and Yeung, A., Photoangioplasty with local motexafin lutetium dehvery reduces macrophages in a rabbit postballoon injury model, Cardiovasc. Res., 49, 449, 2001. 

Yamaguchi, A., Woodburn, K.W., Hayase, M., Hoyt, G., and Robbins, R.C., Photodynamic therapy with motexafin lutetium (Lu-Tex) reduces experimental graft coronary artery disease. Transplant, 71, 1526, 2001. 

---